SCHEMBL4065310

SCHEMBL4065310

CN1CCC[C@@H]1CCO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21591048 1.00
SCHEMBL236633 1.00
SCHEMBL803674 0.93 CYP1A2 (0.62)
SCHEMBL7891041 0.93 CYP1A2 (0.62)
SCHEMBL10359413 0.93 CYP1A2 (0.62)
SCHEMBL24837421 0.91 CYP1A2 (0.66)
Bromide SCHEMBL27620628 0.91 CYP1A2 (0.60)
SCHEMBL2980496 0.87 CYP1A2 (0.50)
SCHEMBL4088645 0.87
SCHEMBL4087890 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118184561-A Synthetic method and application of R-N-methyl-2- (2-hydroxyethyl) pyrrolidine 济宁晟泰药业有限公司 2024-06-14 CN claimed
EP-1478645-A2 QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS Amgen Inc. (US) 2004-11-24 EP claimed
WO-2003066630-A2 QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS AMGEN INC. (US) 2003-08-14 WO claimed
CN-121850925-A Industrial preparation method and application of clemastine fumarate 广东先强药业有限公司 2026-04-14 CN disclosed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 EP disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 US disclosed
CN-118851971-A Efficient synthesis method of clemastine fumarate 南京斯泰尔医药科技有限公司 2024-10-29 CN disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 WO disclosed
CN-118184561-A Synthetic method and application of R-N-methyl-2- (2-hydroxyethyl) pyrrolidine 济宁晟泰药业有限公司 2024-06-14 CN disclosed
CN-118184561-A Synthetic method and application of R-N-methyl-2- (2-hydroxyethyl) pyrrolidine 济宁晟泰药业有限公司 2024-06-14 CN disclosed
CN-118184561-A Synthetic method and application of R-N-methyl-2- (2-hydroxyethyl) pyrrolidine 济宁晟泰药业有限公司 2024-06-14 CN disclosed
EP-1513814-B1 NOVEL PIPERIDINE COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2010-03-17 EP disclosed
US-7619092-B2 Piperidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-11-17 US disclosed
US-20090203763-A1 SUBSTITUTED BENZHYDRYLETHERS AUSPEX PHARMACEUTICALS, INC. (US) 2009-08-13 US disclosed
US-20090203763-A1 SUBSTITUTED BENZHYDRYLETHERS AUSPEX PHARMACEUTICALS, INC. (US) 2009-08-13 US disclosed
US-20090203763-A1 SUBSTITUTED BENZHYDRYLETHERS AUSPEX PHARMACEUTICALS, INC. (US) 2009-08-13 US disclosed
WO-2009094457-A2 SUBSTITUTED BENZHYDRYLETHERS AUSPEX PHARMACEUTICALS (US) 2009-07-30 WO disclosed
WO-2009094457-A2 SUBSTITUTED BENZHYDRYLETHERS AUSPEX PHARMACEUTICALS (US) 2009-07-30 WO disclosed
EP-2079703-A1 INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS F. Hoffmann-Roche AG (CH) 2009-07-22 EP disclosed
WO-2008052898-A1 INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-05-08 WO disclosed